Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Exclusion criteria

• . Squamous cell carcinoma, undifferentiated or other non-adenocarcinoma histologic type of gastric cancer or gastro-esophageal tumor;
• . Subjects with known contraindications to cadonilimab, CapeOX (see package inserts for cadonilimab, oxaliplatin, and capecitabine);
• . Known history of severe intolerance to cadonilimab, oxaliplatin, or capecitabine (i.e., grade 4 toxicity of one of the agents; grade 3-4 toxicity of other concomitant agents is not excluded);
• . Known history of hypersensitivity or hypersensitivity to cadonilimab, oxaliplatin, other platinum compounds, or fluorouracil;
• . Known brain or meningeal metastases:
• . Radiotherapy or any anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy, radio-frequency ablation, traditional Chinese medicine with anti-tumor indications, immunomodulators or tumor embolization, etc.) within 4 weeks prior to the first dose of study treatment;
• . Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies, or any other antibody or drug therapy against T cell co-stimulation or checkpoint pathways;
• . Patients have had other malignancies within the past 5 years or at the same time (except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);